

**Appendix Table 11. DEFENSE.**

Variable	N	Full Sample	Device	Medication Therapy
<b>Recurrent ischemic strokes (primary outcome), events/N</b>		5/120	0/60	5/60
<b>Age in years , mean (sd)</b>	120	51.75 ( 13.78 )	49.27 ( 14.74)	54.23 ( 12.37)
<b>Male Gender</b>	120	67 (55.8%)	33 (55.0%)	34 (56.7%)
<b>White Race</b>	NR			
<b>Smoke</b>	120	26 (21.7%)	10 (16.7%)	16 (26.7%)
<b>Diabetes</b>	120	14 (11.7%)	6 (10.0%)	8 (13.3%)
<b>High Cholesterol</b>	120	43 (35.8%)	18 (30.0%)	25 (41.7%)
<b>Hypertension</b>	120	29 (24.2%)	12 (20.0%)	17 (28.3%)
<b>Prior Stroke</b>	120	6 (5.0%)	3 (5.0%)	3 (5.0%)
<b>Prior Stroke or TIA</b>	120	10 (8.3%)	4 (6.7%)	6 (10.0%)
<b>Atrial Septal Aneurysm</b>	120	58 (48.3%)	29 (48.3%)	29 (48.3%)
<b>Large Sized Shunt<sup>a</sup></b>	120	96 (80.0%)	50 (83.3%)	46 (76.7%)
<b>Presence of a Superficial Infarct<sup>b</sup></b>	120	104 (86.7%)	56 (93.3%)	48 (80.0%)
<b>Index Stroke (vs. TIA)</b>	120	120 (100%)	60 (100%)	60 (100%)

<sup>a</sup>>20 bubbles for all trials except CLOSURE (>25) and CLOSE (>30).

<sup>b</sup>Not reported in PC Trial.

NR, not reported; SD, standard deviation; TIA indicates transient ischemic attack.